205 related articles for article (PubMed ID: 32688070)
21. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
[TBL] [Abstract][Full Text] [Related]
22. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
23. Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues.
Banister SD; Longworth M; Kevin R; Sachdev S; Santiago M; Stuart J; Mack JB; Glass M; McGregor IS; Connor M; Kassiou M
ACS Chem Neurosci; 2016 Sep; 7(9):1241-54. PubMed ID: 27421060
[TBL] [Abstract][Full Text] [Related]
24. Combination Chemistry: Structure-Activity Relationships of Novel Psychoactive Cannabinoids.
Wiley JL; Marusich JA; Thomas BF
Curr Top Behav Neurosci; 2017; 32():231-248. PubMed ID: 27753007
[TBL] [Abstract][Full Text] [Related]
25. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
26. The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism.
Finlay DB; Mackie W; Webb HDJ; Thomsen LR; Nimick M; Rosengren RJ; Marusich JA; Glass M; Wiley JL
Pharmacol Biochem Behav; 2023 Feb; 223():173530. PubMed ID: 36805861
[TBL] [Abstract][Full Text] [Related]
27. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
28. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
29. Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.
Kinsey SG; Wise LE; Ramesh D; Abdullah R; Selley DE; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2013 Jun; 345(3):492-501. PubMed ID: 23412396
[TBL] [Abstract][Full Text] [Related]
30. In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018.
Gamage TF; Barrus DG; Kevin RC; Finlay DB; Lefever TW; Patel PR; Grabenauer MA; Glass M; McGregor IS; Wiley JL; Thomas BF
Pharmacol Biochem Behav; 2020 Jun; 193():172918. PubMed ID: 32247816
[TBL] [Abstract][Full Text] [Related]
31. Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.
Singh H; Schulze DR; McMahon LR
Psychopharmacology (Berl); 2011 Jun; 215(4):665-75. PubMed ID: 21246187
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
33. Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.
Gatch MB; Forster MJ
Psychopharmacology (Berl); 2016 May; 233(10):1901-10. PubMed ID: 26875756
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid-Induced Tetrad in Mice.
Metna-Laurent M; Mondésir M; Grel A; Vallée M; Piazza PV
Curr Protoc Neurosci; 2017 Jul; 80():9.59.1-9.59.10. PubMed ID: 28678398
[TBL] [Abstract][Full Text] [Related]
35. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid pharmacological properties common to other centrally acting drugs.
Wiley JL; Martin BR
Eur J Pharmacol; 2003 Jun; 471(3):185-93. PubMed ID: 12826237
[TBL] [Abstract][Full Text] [Related]
37. Precipitated Δ9-THC withdrawal reduces motivation for sucrose reinforcement in mice.
Eckard ML; Trexler KR; Kotson BT; Anderson KG; Kinsey SG
Pharmacol Biochem Behav; 2020 Aug; 195():172966. PubMed ID: 32526216
[TBL] [Abstract][Full Text] [Related]
38. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.
Serrano A; Vadas E; Ferrer B; Bilbao A; Granado N; Suárez J; Pavon FJ; Moratalla R; Rodríguez de Fonseca F
Psychopharmacology (Berl); 2021 Feb; 238(2):551-557. PubMed ID: 33410990
[TBL] [Abstract][Full Text] [Related]
39. Do you feel it now? Route of administration and Δ
Wiley JL; Lefever TW; Glass M; Thomas BF
Neurotoxicology; 2019 Jul; 73():161-167. PubMed ID: 30953678
[TBL] [Abstract][Full Text] [Related]
40. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.
Tai S; Vasiljevik T; Sherwood AM; Eddington S; Wilson CD; Prisinzano TE; Fantegrossi WE
Drug Alcohol Depend; 2018 Nov; 192():285-293. PubMed ID: 30300803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
